Merck and Hansoh Pharma, a Chinese biopharmaceutical company, have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist.   Under the agreement, Merck gains an exclusive global license to develop, manufacture and commercialize HS-10535. Hansoh Pharma will receive an $112 million upfront and is eligible to receive up to $1.9 billion in milestone payments associated with the development, regulatory approval and ...